ProCE Banner Events

Share

The How and Why of Bispecific Antibodies for R/R DLBCL: Best Practices for Exemplary Care

Expert discussion and takeaways for best practices in the use of bispecific antibodies for the management of relapsed/refractory diffuse large B-cell lymphoma.

Physician Assistants : 1.00 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

This event has expired. No longer available for credits.

Who Should Attend

This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with DLBCL treated with bispecific antibodies.

Time and location

Thursday, October 03, 2024

12:00 PM - 1:00 PM Central Time (CT)

Virtual

Agenda

Bispecifics in Relapsed/Refractory DLBCL

Introduction, Real-world Patient Cases, and Interactive ARS Questions

I. The Role of Bispecific Antibodies in DLBCL: How They Work and Practical Considerations

  • Mechanism of action of bispecific antibodies
  • Key points for patient discussion about bispecific antibodies and how they work

II. Available and Emerging Bispecific Antibodies: Implications for Treatment and Prognosis

  • Current data on epcoritamab and glofitamab in DLBCL
  • Formulating strategies for bispecific antibodies in DLBCL

III. Fundamentals on Bispecific Antibody AE Identification and Management and Addressing Barriers to Treatment

  •  Common AEs associated with bispecific antibody therapy and how they impact patient outcomes and quality of life
  •  What proactive strategies can oncology APPs implement to mitigate the toxicity of bispecific antibodies? 

Closing Remarks and Question and Answer Session

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Diffuse large B-cell lymphoma (DLBCL).

Target Audience
This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with DLBCL treated with bispecific antibodies. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Explain the mechanism of action of novel bispecific antibody therapies vs other anticancer agents and the role of bispecific antibodies in the treatment of DLBCL
  • Design treatment strategies for the use of bispecific antibodies in R/R DLBCL, based on current indications, consensus guidelines, recent key safety and efficacy data, and patient and disease factors
  • Assess patients for eligibility for ongoing clinical trials and for barriers to and disparities in care that may impact outcomes
  • Apply recommendations to mitigate and manage adverse events associated with bispecific antibody treatment in patients with DLBCL

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour, including 1.0 hour of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Acknowledgement

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Clinical Care Options, LLC

Supported by an educational grant from Genmab US, Inc.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.